申请人:PFIZER
公开号:WO2010116270A1
公开(公告)日:2010-10-14
EP2/4 compounds having improved dual pharmacological activity are described. The uniqueness of using EP2/4 dual agonists resides in their ability to modify both uveoscleral outflow via the ciliary muscle and conventional outflow via trabecular meshwork and Schlemm's canal all in the same treatment paradigm. The compounds can be employed for the treatment of glaucoma and ocular hypertension. Formula (I).
描述了具有改进的双重药理活性的EP2/4化合物。使用EP2/4双激动剂的独特之处在于它们能够通过睫状肌修改虹膜房和通过网状层和Schlemm氏管的传统流出,这一切都在同一治疗范式中。这些化合物可用于治疗青光眼和眼压增高。公式(I)。